Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sympathetic nervous system signaling refers to the complex network of neurotransmitters, receptors, and neural pathways that mediate the actions of the sympathetic division of the autonomic nervous system. This system is responsible for orchestrating the body's "fight-or-flight" response to stress or danger by increasing heart rate, dilating pupils, redirecting blood flow to muscles, stimulating sweat production, mobilizing energy stores through glucose release, and inhibiting non-essential functions like digestion[3][7]. The process involves two main types of neurons—preganglionic neurons originating in the thoracolumbar spinal cord segments (T1-L2/L3), which release acetylcholine onto nicotinic receptors in sympathetic ganglia; and postganglionic neurons that typically release norepinephrine onto adrenergic receptors at target organs[1][4][5]. There are notable exceptions where acetylcholine is released at sweat glands or dopamine at renal vasculature[1]. Sympathetic nervous system signaling is not a single molecular target but rather a physiological pathway involving multiple molecular targets such as adrenergic receptors (alpha and beta subtypes), muscarinic cholinergic receptors in certain tissues, enzymes involved in neurotransmitter synthesis/degradation, ion channels regulating neuronal excitability, etc.[5]. Drugs targeting this pathway include adrenergic agonists/antagonists like beta-blockers or alpha-blockers; however these drugs act on specific receptor proteins within this broader pathway. Because "sympathetic nervous system signaling" describes an entire physiological process rather than a discrete molecule or receptor protein suitable as a drug target entry—it should not be considered a canonical therapeutic target itself. Instead it encompasses many individual targets such as "Beta 1 adrenergic receptor," "Alpha 2 adrenergic receptor," etc., each with their own structured information. Therefore: This entry is incorrect as a druggable molecular target. It represents an entire functional axis/pathway rather than an individual protein/receptor/enzyme/transporter suitable for direct pharmacological targeting[1][4][5]. If you need structured information on specific components within sympathetic nervous system signaling—such as particular adrenergic receptor subtypes—please specify those molecules individually.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sympathetic nervous system signaling (null).